Nordstrom to succeed Torre as McCann Healthcare chief executive

Share this article:
Richard Nordstrom has been named to succeed Joe Torre as global chief executive of McCann Healthcare Worldwide, a division of Interpublic Group's McCann Worldgroup. Torre will continue with McCann Healthcare Worldwide as chairman.
"I will be taking on a role focusing more on relationships and less on numbers," Torre said.
Nordstrom most recently was president of the New York office of Corbett Accel.
Scott Cotherman, chief executive of Corbett Accel, has stepped in as acting president of the New York office on an interim basis.
Nordstrom joined the Chicago-based Corbett Healthcare Group in 1998 as senior vice president, director of client services.
In early 2004, Omnicom divisions Corbett and Accel merged to form Corbett Accel. Accounts under Nordstrom's supervision there were Merck, Bristol-Myers Squibb, Sanofi-Synthelabo and Shire Pharmaceuticals.
Nordstrom is expected to begin his new role Jan. 3.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...